Your browser doesn't support javascript.
Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.
El Rifay, Amira S; Mahmoud, Sara H; Marouf, Mohamed A; Gomaa, Mokhtar R; El Taweel, Ahmed; Abo Shama, Noura M; GabAllah, Mohamed; Abd El Dayem, Soha M; Kandeil, Ahmed; Mostafa, Ahmed; El-Shesheny, Rabeh; Kayali, Ghazi; Ali, Mohamed A.
  • El Rifay AS; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Mahmoud SH; Child Health Department, National Research Centre, Giza, Egypt.
  • Marouf MA; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Gomaa MR; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • El Taweel A; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Abo Shama NM; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • GabAllah M; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Abd El Dayem SM; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Kandeil A; Paediatrics Department, National Research Centre, Giza, Egypt.
  • Mostafa A; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • El-Shesheny R; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Kayali G; Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt.
  • Ali MA; Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, Texas, USA.
Influenza Other Respir Viruses ; 15(6): 750-756, 2021 11.
Article in English | MEDLINE | ID: covidwho-1311033
ABSTRACT

BACKGROUND:

Reported laboratory-confirmed COVID-19 cases underestimate the true burden of disease as cases without laboratory confirmation, and asymptomatic and mild cases are missed by local surveillance systems. Population-based seroprevalence studies can provide better estimates of burden of disease by taking into account infections that were missed by surveillance systems. Additionally, little is known about the determinants of seroconversion in community settings.

METHODS:

We conducted a cross-sectional serologic survey among 888 participants in Egypt.

RESULTS:

Neutralizing antibodies were detected in 30% of study volunteers. Age and educational level were associated with being seropositive as people older than 70 years and people with graduate degrees had lower seroprevalence. Self-reporting cases having COVID-19-related symptoms such as fever, malaise, headache, dyspnea, dry cough, chest pain, diarrhea, and loss of taste or smell were all associated with having antibodies. Fever and loss of taste or smell were strong predictors with odds ratios of 2.1 (95% confidence interval 1.3-3.5) and 4.5 (95% confidence interval 2.6-7.8), respectively.

CONCLUSIONS:

Our results can guide COVID-19 prevention and control policies and assist in determining the immunity level in some Egyptian communities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: Irv.12889

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: Influenza Other Respir Viruses Journal subject: Virology Year: 2021 Document Type: Article Affiliation country: Irv.12889